GENOMIC TEST IMPROVES FORECAST OF RECURRENCE IN NSCLC

Using a form of genomic profiling for early non-small-cell lung cancer (NSCLC), researchers here believe they can cherry pick those patients who will benefit most from adjuvant chemotherapy. In laboratory models, the so-called Lung Metagene Predictor was up to 90% accurate in picking which patients would have a recurrence of their cancer after surgery, according to Anil Potti, M.D., of the Duke University Medical Center.
MedPage Today